Bluejay Diagnostics Inc. (BJDX)
NasdaqCM: BJDX
· Real-Time Price · USD
1.05
+0.00 (0.00%)
At close: Aug 13, 2026, 2:22 PM
Bluejay Diagnostics Inc. (BJDX) Stock Price, Analysis & Data
0.00% (1D)
| Bid | 0.75 |
| Market Cap | 1.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -6.9M |
| Beta | 0.89 |
| EPS (ttm) | -3.74 |
| PE Ratio (ttm) | n/a |
| Forward PE | -3.28 |
| P/B (ttm) | 0.26 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 1.31 |
| Volume | 208,071 |
| Avg. Volume (20D) | 5,973,753 |
| Open | 1.00 |
| Previous Close | 1.05 |
| Day's Range | 1.00 - 1.07 |
| 52-Week Range | 0.83 - 16.68 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BJDX
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force...
Industry Medical Devices
Sector Healthcare
IPO Date Nov 10, 2021
Employees 6
Stock Exchange NasdaqCM
Ticker Symbol BJDX
Website https://bluejaydx.com
Financial Performance
In 2025, Bluejay Diagnostics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -6.85M, a decrease of -11.26%.
Financial StatementsEarnings Surprise
Bluejay Diagnostics has released their quarterly earnings on Mar 28, 2024: